Diabetic Retinopathy Clinical Trial
Official title:
To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation
Lacunae in Knowledge No study is available in literature regarding visual field impairment
in proliferative diabetic retinopathy comparing conventional double frequency Nd:YAG
panretinal photocoagulation with PASCAL panretinal photocoagulation
AIMS & OBJECTIVE
1. To compare visual field impairment in conventional double frequency Nd: YAG panretinal
photocoagulation with PASCAL panretinal photocoagulation.
2. To examine the effect of these modalities of laser on macular edema
60 eyes of proliferative diabetic retinopathy will undergo humphery visual field
analysis,and optical coherence tomography before and after panretinal photocoagulation
Material and Methods
1.Study will be prospective randomized interventional case series. Methods: 60 eyes of
proliferative diabetic retinopathy (clear media with no vitreous/significant preretinal
hemorrhage) will be taken for the study, out of which 30 eyes will undergo panretinal
photocoagulation by conventional frequency doubled Nd: YAG laser and remaining 30 eyes will
be by PASCAL laser.
All patients will undergo routine ophthalmic examination (visual acuity, slit lamp, indirect
ophthalmoscope, IOP) as well as FFA/seven fields fundus photos (whenever required),
OCT(optoview spectral domain OCT), visual fields (Humphrey 30-2 SITA Standard and 60-1) and
baseline blood investigation will be done before 1st sitting of laser. Written informed
consent will be taken by all the subjects. PRP will be completed in 2-3 sitting at 3 days
interval with one spots apart and moderate intensity gray burns will be given between arcade
to periphery. In case of clinical significant macular edema modified grid/ focal laser of
mild intensity spots will be done. At each visit patient will be assessed for visual acuity,
OCT, IOP (applanation tonometer). Patients will be followed up for at least 3 months. After
the completion of last sitting of photocoagulation, follow-up will be at one month and 3
months. At one month follow up together with routine ophthalmic examination, OCT, HVF
30-2,60-1 will be done. At final follow-up at 3 months HVF 30-2,60-1,OCT will be done in
addition of routine ophthalmic examination and FFA will be done whenever indicated.
Inclusion Criteria
1. 60 eyes of diabetic patients with proliferative DR will be included.
2. Visual acuity 20/50 or better in all patients.
3. Patients available for follow up at least twice between 4-12 weeks.
4. Patients giving consent for panretinal photocoagulation and for inclusion in study
Exclusion Criteria
1. Patients with diseases known to affect visual field as such as aphakia, cataract,
glaucoma, optic nerve and macular diseases, will be excluded from the study.
2. Previous photocoagulation(macular laser or PRP) will also be an exclusion criterion.
Out come Measure
1. Comparison of the two methods in relation to visual field loss(in previous studies
average deterioration in visual field(MD) was 3-5dB in 45% cases) in terms of MD,CPSD
and each quadrants loss of fields and number of patients worsened the visual fields and
which method will be superior in term of less visual field loss.
2. Effect on macular edema in terms of OCT thickness
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03660371 -
ILM Peeling in PDR Patients Undergoing PPV for VH
|
N/A | |
| Completed |
NCT03660384 -
Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy
|
N/A | |
| Completed |
NCT03660345 -
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
|
Phase 3 | |
| Completed |
NCT04905459 -
ARDA Software for the Detection of mtmDR
|
||
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
| Completed |
NCT05022615 -
Comparing 3 Imaging Systems
|
||
| Completed |
NCT00385333 -
Metabolic Mapping to Measure Retinal Metabolism
|
Phase 2 | |
| Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
| Completed |
NCT03702374 -
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
|
Phase 3 | |
| Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
| Completed |
NCT04009980 -
Long-term Retinal Changes After Topical Citicoline Administration in Patients With Mild Signs of Diabetic Retinopathy in Type 1 Diabetes Mellitus.
|
N/A | |
| Completed |
NCT02924311 -
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
|
||
| Not yet recruiting |
NCT06257082 -
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
|
N/A | |
| Not yet recruiting |
NCT05452993 -
Screening for Diabetic Retinopathy in Pharmacies With Artificial Intelligence Enhanced Retinophotography
|
N/A | |
| Withdrawn |
NCT02812030 -
Aflibercept for Retinopathy in the Real World
|
N/A | |
| Completed |
NCT02391558 -
Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography
|
N/A | |
| Active, not recruiting |
NCT02330042 -
OCT Biomarkers for Diabetic Retinopathy
|
||
| Active, not recruiting |
NCT02353923 -
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
|
N/A | |
| Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |